Beovu (brolucizumab-dbll)

No dosing information is available for this tab.

Brolucizumab-dbll is administered by intravitreal injection into the affected eye(s). Only qualified clinicians should administer the drug. Because of the risk of infection and endophthalmitis, proper aseptic technique must be used when preparing and administering the drug.

Brolucizumab-dbll is commercially available in single-use vials containing 6 mg of the drug for intravitreal injection. Prior to administration, the vial should be allowed to come to room temperature. Brolucizumab-dbll injection should be inspected visually for particulate matter, cloudiness, or discoloration; the solution should appear clear to slightly opalescent and colorless to slightly brownish-yellow, and should not be used if it contains particles or appears cloudy or discolored. The entire contents of the vial should be withdrawn through a sterile 5-mcm, 18-gauge filter needle (provided by the manufacturer) into a 1-mL syringe. The filter needle is then replaced with a sterile 30-gauge, 1/2-inch needle for intravitreal injection. Air should be expelled from the syringe and the plunger tip aligned to the 0.05-mL mark on the syringe.

Immediately following preparation of the dose, brolucizumab-dbll should be injected under aseptic conditions (including use of surgical hand disinfection, sterile gloves, a sterile drape, sterile eyelid speculum (or equivalent), and availability of sterile paracentesis equipment (if required)) following adequate anesthesia and administration of a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid, and ocular surface.

Each vial of brolucizumab-dbll should be used for treatment of a single eye only. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drape, eyelid speculum, and filter and injection needles should be changed before brolucizumab is administered to the other eye.

Immediately following intravitreal injection, patients should be monitored for elevation in intraocular pressure (IOP) using tonometry or by checking for perfusion of the optic nerve head. (See Increased Intraocular Pressure under Cautions: Warnings/Precautions.) Patients should be instructed to immediately report any manifestations suggestive of endophthalmitis or retinal detachment. (See Endophthalmitis and Other Serious Ocular Effects under Cautions: Warnings/Precautions.)

Brolucizumab-dbll injection should be stored at 2-8degreesC in the original carton; the injection should not be frozen and should be protected from light. The unopened vial may be stored at 20-25degreesC for up to 24 hours prior to use.

No dosing information is available for this tab.

No formal drug interaction studies have been conducted to date with brolucizumab.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

Brolucizumab is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity (e.g., rash, pruritus, urticaria, erythema, severe intraocular inflammation) to brolucizumab or any ingredient in the formulation.

• Lactation
• Ocular infection

• Ocular inflammation
• Pregnancy

• Ocular hypertension

Adverse effects occurring in 5% or more of patients receiving intravitreal therapy with brolucizumab-dbll include blurred vision, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters.

More Frequent

• Cataracts

Less Frequent

• Corneal abrasion
• Hypersensitivity drug reaction
• Punctate keratitis
• Retinal hemorrhage
• Retinal tear
• Retinal vascular occlusion
• Tear of retinal pigment epithelium
• Transient blindness
• Vitreous detachment

Rare or Very Rare

• Amaurosis
• Arterial thrombosis
• Endophthalmitis
• Ocular hypertension
• Retinal detachment
• Retinal pigment epithelial detachment
• Retinal vasculitis
• Vitreous hemorrhage

More Frequent

• Blurred vision
• Conjunctival hemorrhage
• Ocular pain
• Vitreous floater

Less Frequent

• Conjunctival hyperemia
• Conjunctivitis
• Erythema
• Eye tearing
• Foreign body sensation of eye
• Ocular inflammation
• Pruritus of skin
• Skin rash
• Urticaria

Rare or Very Rare

• Scleritis

No enhanced messaging available.

Safety and efficacy of brolucizumab have not been established in pediatric patients.

There are no adequate and well-controlled studies of brolucizumab in pregnant women. Based on its mechanism of action, brolucizumab may adversely affect embryofetal development or reproductive capacity. In animal studies, VEGF inhibition has been shown to cause malformations, embryofetal resorption, and decreased fetal weight and also to affect follicular development, corpus luteum function, and fertility.

Brolucizumab should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. Women of reproductive potential should be advised to use highly effective methods of contraception during brolucizumab therapy and for at least one month after the last dose of the drug.

It is not known whether brolucizumab distributes into human milk, affects the breast-fed infant, or affects milk production.

Breast-feeding is not recommended during brolucizumab therapy and for at least one month after the last dose of the drug.

In clinical trials, approximately 90% of patients receiving brolucizumab-dbll were 65 years of age or older and 60% were 75 years of age or older. No substantial differences in efficacy or safety were observed with increasing age in these studies. No dosage adjustment is required in patients 65 years of age or older.